This study investigated the incidence and severity of pneumonitis in stage III NSCLC patients receiving Atezolizumab as consolidation therapy after concurrent chemoradiation. Of 14 patients, 8 developed pneumonitis. Age, gender, and smoking status did not significantly affect pneumonitis risk. Histology may be a factor, with a higher incidence in squamous cell carcinoma, although this was not statistically significant due to the small sample size. The study highlights the significant risk of pneumonitis with Atezolizumab post chemoradiation and calls for larger studies.
Publisher
Asian Pacific Journal of Cancer Prevention
Published On
Mar 12, 2023
Authors
Lili Jose Saade, Arafat Tfayli
Tags
pneumonitis
Atezolizumab
NSCLC
chemoradiation
squamous cell carcinoma
oncology
patient safety
Related Publications
Explore these studies to deepen your understanding of the subject.
